Original language | English (US) |
---|---|
Pages (from-to) | 1064-1065 |
Number of pages | 2 |
Journal | JAMA Oncology |
Volume | 7 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2021 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JAMA Oncology, Vol. 7, No. 7, 07.2021, p. 1064-1065.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Risk, Racial Disparity, and Outcomes among Patients with Cancer and COVID-19 Infection
AU - Kumar, Vaibhav
AU - Grant, Megan
AU - Martin, Karlyn A.
N1 - Funding Information: Conflict of Interest Disclosures: Dr Pond reported personal fees from Takeda, AstraZeneca, Merck, and Profound Medical outside the submitted work, as well as Independent Data Monitoring Committee (IDMC) membership for Takeda; and a family member who is an employee of Roche Canada Ltd, and who owns stock in Roche. Dr Brastianos reported personal fees from Angiochem, Genentech-Roche, Eli Lilly, Tesaro, Voyager Therapeutics, ElevateBio, Pfizer, Array, SK Life Sciences, Dantari, and Merck, and grants from Merck, Eli Lilly, and Mirati outside the submitted work. Dr Das reported serving as CNS Tumour Lead for Cancer Care Ontario, speaker fees from Society for NeuroOncology, American Association of Neurological Surgery, Congress of Neurological Surgeons, personal fees from Subcortical Surgery Group Advisory Board, nonfinancial support from Xpan Medical Advisory Board, and grants from Medicenna and Alkermes outside the submitted work. Dr Sahgal reported advisory and consulting fees from Varian, Elekta (Gamma Knife Icon), and BrainLAB; grants from Elekta AB and Varian, personal fees from Elekta, Varian, and BrainLAB; honoraria from AstraZeneca, Elekta AB, Varian, BrainLAB, and Medtronic Kyphon; board membership for the International Stereotactic Radiosurgery Society and AO Spine Knowledge Forum Tumor; and membership to the Elekta MR Linac Research Consortium, Elekta Spine, Oligometastases and Linac Based SRS Consortia. Dr Jerzak reported personal fees from Amgen, AstraZeneca, Apo Biologix, Eli Lilly, Esai, Genomic Health, Knight Therapeutics, Merck, Myriad Genetics Inc, Pfizer, Roche, Novartis, and Purdue Pharma, and grants from AstraZeneca and Eli Lilly outside the submitted work. No other disclosures were reported.
PY - 2021/7
Y1 - 2021/7
UR - http://www.scopus.com/inward/record.url?scp=85105843880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105843880&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2021.0768
DO - 10.1001/jamaoncol.2021.0768
M3 - Letter
C2 - 33956053
AN - SCOPUS:85105843880
SN - 2374-2437
VL - 7
SP - 1064
EP - 1065
JO - JAMA oncology
JF - JAMA oncology
IS - 7
ER -